Zion Oil & Gas (ZNOG) 10-Q 10 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Document Information Line Items
Entity Registrant Name	ZION OIL & GAS, INC.
Trading Symbol	N/A
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		475,236,141
Amendment Flag	false
Entity Central Index Key	0001131312
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0065053
Entity Address, Address Line One	12655 N Central Expressway
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75243
Title of 12(b) Security	N/A
Security Exchange Name	NONE
City Area Code	(214)
Local Phone Number	221-4610
Entity Interactive Data Current	Yes
Entity File Number	001-33228

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 5,755	$ 4,683
Fixed short-term bank and escrow deposits – restricted	1,319	1,269
Prepaid expenses and other	437	689
Other deposits	549	617
Governmental receivables	864	900
Other receivables	158	483
Total current assets	9,082	8,641
Unproved oil and gas properties, full cost method (see Note 4)	53,250	46,950
Property and equipment at cost
Drilling rig and related equipment, net of accumulated depreciation of $1,075 and $704 (see note 2I)	6,638	6,834
Property and equipment, net of accumulated depreciation of $626 and $604	132	138
Property Plant and Equipment Net	6,770	6,972
Right of Use Lease Assets (see Note 5)	335	327
Other assets
Assets held for severance benefits	454	541
Total other assets	454	541
Total assets	69,891	63,431
Current liabilities
Accounts payable	1,658	2,783
Lease obligation – current (see Note 5)	261	203
Asset retirement obligation	571	571
Accrued liabilities	588	1,781
Total current liabilities	3,078	5,338
Long-term liabilities
Lease obligation – non-current (see Note 5)	83	169
Provision for severance pay	488	548
Total long-term liabilities	571	717
Total liabilities	3,649	6,055
Commitments and contingencies (see Note 6)
Stockholders’ equity
Common stock, par value $.01; Authorized: 800,000,000 shares at June 30, 2022: Issued and outstanding: 473,777,378 and 364,322,883 shares at June 30, 2022 and December 31, 2021, respectively	4,738	3,643
Additional paid-in capital	289,792	277,258
Accumulated deficit	(228,288)	(223,525)
Total stockholders’ equity	66,242	57,376
Total liabilities and stockholders’ equity	$ 69,891	$ 63,431

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Drilling rig and related equipment, net of accumulated depreciation (in Dollars)	$ 1,075	$ 704
Accumulated depreciation (in Dollars)	$ 626	$ 604
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	800,000,000	800,000,000
Common stock, issued	473,777,378	364,322,883
Common stock, outstanding	473,777,378	364,322,883

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
General and administrative	$ 1,550	$ 2,952	$ 2,985	$ 4,923
Impairment of unproved oil and gas properties
Other	946	1,064	1,657	1,856
Loss from operations	(2,496)	(4,016)	(4,642)	(6,779)
Other income (expense), net
Gain on derivative liability		5		431
Foreign exchange gain (loss)	(81)	13	(90)	(50)
Financial expenses, net	(20)	(58)	(31)	(218)
Loss, before income taxes	(2,597)	(4,056)	(4,763)	(6,616)
Income taxes
Net loss	$ (2,597)	$ (4,056)	$ (4,763)	$ (6,616)
Net (loss), gain per share of common stock
Basic and diluted (in US$) (in Dollars per share)	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.03)
Weighted-average shares outstanding
Basic and diluted (in thousands) (in Shares)	471,946	248,672	439,039	244,032

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Basic and diluted (in US$)	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.03)
Basic and diluted (in thousands)	471,946	248,672	439,039	244,032

Consolidated Condensed Statem_3

Consolidated Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock		Additional paid-in Capital	Accumulated deficit	Total
Balances at Dec. 31, 2020	$ 2,374		$ 245,539	$ (212,804)	$ 35,109
Balances (in Shares) at Dec. 31, 2020	237,382
Funds received from sale of DSPP units and shares and exercise of warrants	$ 400		13,388		13,788
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	39,933
Costs associated with the issuance of shares			(115)		(115)
Value of bonds converted to shares		[1]	9		9
Value of bonds converted to shares (in Shares)	15
Bond interest paid in shares	$ 5		316		321
Bond interest paid in shares (in Shares)	530
Bond principal paid in shares	$ 53		3,161		3,214
Bond principal paid in shares (in Shares)	5,296
Funds received from option exercises	$ 1				1
Funds received from option exercises (in Shares)	117
Value of options granted to employees, directors and others as non-cash compensation			2,589		2,589
Net loss				(6,616)	(6,616)
Balances at Jun. 30, 2021	$ 2,833		264,887	(219,420)	48,300
Balances (in Shares) at Jun. 30, 2021	283,273
Balances at Mar. 31, 2021	$ 2,414		249,170	(215,364)	36,220
Balances (in Shares) at Mar. 31, 2021	241,351
Funds received from sale of DSPP units and shares and exercise of warrants	$ 361		10,578		10,939
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	36,085
Costs associated with the issuance of shares			(115)		(115)
Value of bonds converted to shares		[1]	9		9
Value of bonds converted to shares (in Shares)	11
Bond interest paid in shares	$ 5		316		321
Bond interest paid in shares (in Shares)	530
Bond principal paid in shares	$ 53		3,161		3,214
Bond principal paid in shares (in Shares)	5,296
Funds received from option exercises
Value of options granted to employees, directors and others as non-cash compensation			1,768		1,768
Net loss				(4,056)	(4,056)
Balances at Jun. 30, 2021	$ 2,833		264,887	(219,420)	48,300
Balances (in Shares) at Jun. 30, 2021	283,273
Balances at Dec. 31, 2021	$ 3,643		277,258	(223,525)	57,376
Balances (in Shares) at Dec. 31, 2021	364,324
Funds received from sale of DSPP units and shares and exercise of warrants	$ 1,094		11,899		12,993
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	109,349
Funds received from option exercises	$ 1				1
Funds received from option exercises (in Shares)	105
Value of options granted to employees, directors and others as non-cash compensation			635		635
Net loss				(4,763)	(4,763)
Balances at Jun. 30, 2022	$ 4,738		289,792	(228,288)	66,242
Balances (in Shares) at Jun. 30, 2022	473,778
Balances at Mar. 31, 2022	$ 4,666		287,878	(225,691)	66,853
Balances (in Shares) at Mar. 31, 2022	466,593
Funds received from sale of DSPP units and shares and exercise of warrants	$ 72		1,494		1,566
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	7,130
Funds received from option exercises		[1]				[1]
Funds received from option exercises (in Shares)	55
Value of options granted to employees, directors and others as non-cash compensation			420		420
Net loss				(2,597)	(2,597)
Balances at Jun. 30, 2022	$ 4,738		$ 289,792	$ (228,288)	$ 66,242
Balances (in Shares) at Jun. 30, 2022	473,778
[1] Less than one thousand.

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (4,763)	$ (6,616)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	392	368
Cost of options issued to employees, directors and others as non-cash compensation	618	2,589
Amortization of debt discount related to convertible bonds		190
Change in derivative liability		(431)
Change in assets and liabilities, net:
Other deposits	68	8
Prepaid expenses and other	252	1,366
Governmental receivables	36	501
Lease obligation – current	58	(63)
Lease obligation – non current	(86)	(74)
Right of use lease assets	(8)	115
Other receivables	325	9
Severance payable, net	27	(45)
Accounts payable	(357)	(91)
Accrued liabilities	14	(792)
Net cash used in operating activities	(3,424)	(2,966)
Cash flows from investing activities
Acquisition of property and equipment	(15)	(43)
Acquisition of drilling rig and related equipment	(346)	(98)
Investment in unproved oil and gas properties	(8,087)	(14,903)
Net cash used in investing activities	(8,448)	(15,044)
Cash flows from financing activities
Costs paid related to the issuance of new shares		(115)
Proceeds from exercise of stock options	1	1
Proceeds from issuance of stock and exercise of warrants	12,993	13,788
Net cash provided by financing activities	12,994	13,674
Net increase in cash, cash equivalents and restricted cash	1,122	(4,336)
Cash, cash equivalents and restricted cash – beginning of period	5,952	14,662
Cash, cash equivalents and restricted cash – end of period	7,074	10,326
Non-cash investing and financing activities:
Cost of options capitalized to oil & gas properties	17
Convertible Bond interest paid in shares		321
Convertible Bond principal paid in shares		3,214
Unpaid investments in oil & gas properties	1,691	2,798
10% Senior Convertible Bonds converted to shares		9
Capitalized convertible bond interest attributed to oil and gas properties		104
New lease accounted for as a right of use lease asset	$ 136	$ 128

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Income Statement [Abstract]
Cash and cash equivalents	$ 5,755	$ 4,683	$ 9,047	$ 11,708
Restricted cash included in fixed short-term bank deposits	1,319	1,269	1,279	2,954
Total	$ 7,074	$ 5,952	$ 10,326	$ 14,662

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Going Concern	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Nature of Operations, Basis of Presentation and Going Concern	Note 1 - Nature of Operations, Basis of Presentation and Going Concern A. Nature of Operations Zion Oil & Gas, Inc., a Delaware corporation (“we,” “our,” “Zion” or the “Company”) is an oil and gas exploration company with a history of 22 years of oil & gas exploration in Israel. As of June 30, 2022, the Company has no revenues from its oil and gas operations. Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company’s operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company. On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts. On January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect. Zion has the trademark “ZION DRILLING” filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel. Exploration Rights/Exploration Activities Megiddo-Jezreel Petroleum License, No. 401 (“MJL 401”) and New Megiddo License 428 (“NML 428”) The Megiddo-Jezreel License 401 was awarded on December 3, 2013 for a three-year primary term through December 2, 2016 with the possibility of additional one-year extensions up to a maximum of seven years. The Megiddo-Jezreel License 401 lies onshore, south and west of the Sea of Galilee, and we continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential. The NML 428 (covering the same area as MJL 401) was awarded on December 3, 2020 for a six-month term with the possibility of an additional six-month extension. On April 29, 2021, Zion submitted a request to the Ministry of Energy for a six-month extension to December 2, 2021. On May 30, 2021, the Ministry of Energy approved our request for extension to December 2, 2021. On November 29, 2021, the Ministry of Energy approved our request for extension to August 1, 2022. On July 25, 2022, Zion submitted a request to the Ministry of Energy for a six-month extension to February 1, 2023. On July 31, 2022, the Ministry of Energy approved our request for extension to February 1, 2023. This license effectively replaced the Megiddo-Jezreel License 401 as it has the same area and coordinates. Zion spudded its MJ-02 exploratory well on January 6, 2021. On November 23, 2021, Zion announced via a press release that it completed drilling the MJ-02 well to a total depth of 5,531 meters (~18,141 feet) with a 6 inch open hole at that depth. A full set of detailed and comprehensive tests including neutron-density, sonic, gamma, and resistivity logs were acquired in December 2021, as a result of which we identified an encouraging zone of interest. Extensive well testing operations are continuing for the MJ-02 well. B. Basis of Presentation The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three months ended June 30, 2022 are not necessarily indicative of the operating results for the year ending December 31, 2022 or for any other subsequent interim period. C. Going Concern The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons. The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The Company’s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, the Company’s ability to continue as a going concern may be impaired. The consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the six months ended June 30, 2022, the Company incurred a net loss of approximately $4.8 million and had an accumulated deficit of approximately $228.3 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern. To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies A. Net Gain (Loss) per Share Data Basic and diluted net (loss) gain per share of common stock, par value $0.01 per share (“Common Stock”), is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share, as the inclusion of 37,061,435 and 34,216,856 and 16,426,527 and 15,248,643 Common Stock equivalents in the three and six-month period ended June 30, 2022 and 2021 respectively, would be anti-dilutive. B. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates. C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the three and six months ended June 30, 2022, and 2021, respectively, the Company did not record any post-impairment charges. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $53,250,000 and $46,950,000 as of June 30, 2022 and December 31, 2021, respectively. D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At June 30, 2022, and December 31, 2021, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. Derivative instruments are carried at fair value, generally estimated using the Binomial Model. E. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. F. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period, or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity G. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report. H. Recently Adopted Accounting Pronouncements ASU 2016-02 – Leases (Topic 842) In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”) in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. Zion adopted ASU 2016-02 in the first quarter of 2019. Presently, Zion has operating leases for office space in Dallas, Texas and in Caesarea, Israel plus various leases for motor vehicles. These leases have been accounted for under ASU 2016-02 in 2020, 2021 and 2022 by establishing a right-of-use asset and a corresponding current lease liability and non-current lease liability. Zion is not subject to any loan covenants and therefore, the increase in assets and liabilities does not have a material impact on its business. ASU 2020-03, “Codification Improvements to Financial Instruments” In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its consolidated financial statements. In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company does not believe that this ASU will have any impact on its consolidated financial statements. The Company does not believe that the adoption of any of the recently issued accounting pronouncements had a significant impact on our consolidated financial position, results of operations, or cash flow, except for ASC Update No. 2016-02—Leases, which requires organizations to recognize lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP. See Note 5 for more complete details on balances at June 30, 2022 and December 31, 2021. It is the Company’s practice to review any newly established Accounting Standard Updates with each reporting period. As of June 30, 2022, and through the filing date of this report, no recently issued updates have been found applicable to have a material effect on the Company’s financial statements. I. Depreciation and Accounting for Drilling Rig and Related Equipment On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. We remitted to the Seller $250,000 on February 6, 2020 as earnest money towards the purchase price. The Closing anticipated by the Agreement took place on March 12, 2020 by the Seller’s execution and delivery of a Bill of Sale to us. On March 13, 2020, the Seller retained the earnest money deposit, and the Company remitted $4,350,000 to the seller towards the purchase price and $1,000,000 (the “Holdback Amount”) was deposited in escrow with American Stock Transfer and Trust Company LLC, as escrow agent, through November 30, 2020, or as extended by mutual agreement of the parties, pending a determination, if any, by us of any operating deficiency in the drilling rig. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021. Since the rig purchase closed during March 2020, it was recorded on Zion’s books as a long-term fixed asset as a component of Property and Equipment. The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion will depreciate the rig on a straight-line basis. The $540,000 in spare parts was the original cost to CED. These items were received and counted by Zion upon receipt. All records and files are maintained by Zion. Zion plans to obtain a physical count of the equipment items at the end of each quarter, or as close to such date as practical, in accordance with our normal procedures. Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly. See the table below for a reconciliation of the rig-related activity during the six months ended June 30, 2022: I-35 Drilling Rig & Associated Equipment: Six-month period ended June 30, 2022 I-35 Rig Other Total US$ US$ US$ US$ December 31, 2021 5,859 642 333 6,834 Asset Additions - 135 211 346 Asset Depreciation (317 ) - (54 ) (371 ) Asset Disposals for Self-Consumption - (171 ) - (171 ) June 30, 2022 5,542 606 490 6,638

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 3 - Stockholders’ Equity The Company’s shareholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01, that the Company is authorized to issue from 400,000,000 shares to 800,000,000 shares, effective June 9, 2021. A. 2011 Equity Incentive Stock Option Plan During the six months ended June 30, 2022, the Company did not grant any options from the 2011 Equity Incentive Plan for employees, directors and consultants. During the six months ended June 30, 2021, the Company granted the following options from the 2011 Equity Incentive Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 600,000 shares of Common Stock to six senior officers and three staff members at an exercise price of $0.915 per share. The options vested upon grant and are exercisable through January 4, 2031. The fair value of the options at the date of grant amounted to approximately $456,000. ii. Options to purchase 75,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 6, 2031. The fair value of the options at the date of grant amounted to approximately $68,000. These options were granted per the provisions under the Israeli Appendix to the Plan. iii. Options to purchase 1,800,000 shares of Common Stock to six senior officers and three staff members at an exercise price of $0.59 per share. The options vested upon grant and are exercisable through May 21, 2031. The fair value of the options at the date of grant amounted to approximately $885,000. iv. Options to purchase 200,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through May 21, 2031. The fair value of the options at the date of grant amounted to approximately $117,000. These options were granted per the provisions under the Israeli Appendix to the Plan. B. 2011 Non-Employee Directors Stock Option Plan During the six months ended June 30, 2022, the Company did not grant any qualified (market value) options from the 2011 Non-Employee Directors Stock Option Plan to its directors. During the six months ended June 30, 2021, the Company granted the following qualified (market value) and non-qualified options from the 2011 Non-Employee Directors Stock Option Plan for directors to purchase shares of common stock as non-cash compensation: i. Options to purchase 350,000 shares of Common Stock to seven board members at an exercise price of $0.915 per share. The options vested upon grant and are exercisable through January 4, 2027. The fair value of the options at the date of grant amounted to approximately $252,000. ii. Options to purchase 50,000 shares of Common Stock to one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2027. The fair value of the options at the date of grant amounted to approximately $45,000. These options were granted per the provisions under the Israeli Appendix to the Plan. iii. Options to purchase 1,400,000 shares of Common Stock to six board members and one consultant at an exercise price of $0.59 per share. The options vested upon grant and are exercisable through May 21, 2027. The fair value of the options at the date of grant amounted to approximately $643,000. iv. Options to purchase 200,000 shares of Common Stock to one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through May 21, 2027. The fair value of the options at the date of grant amounted to approximately $116,000. These options were granted per the provisions under the Israeli Appendix to the Plan. C. 2021 Incentive Stock Option Plan Effective June 9, 2021, the Company’s shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan (“Omnibus Plan”) for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock. The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions. The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant. During the six months ended June 30, 2022, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 175,000 shares of Common Stock to six senior officers and one staff member at an exercise price of $0.1529 per share. The options vested upon grant and are exercisable through January 4, 2032. The fair value of the options at the date of grant amounted to approximately $22,000. ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $4,000. iii. Options to purchase 300,000 shares of Common Stock to one senior officer and one staff member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $39,000. iv. Options to purchase 200,000 shares of Common Stock one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $29,000. v. Options to purchase 1,600,000 shares of Common Stock to five senior officers and four staff members at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $209,000, and will be recognized during the years 2022 and 2023. vi. Options to purchase 1,400,000 shares of Common Stock to seven board members, at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $182,000, and will be recognized during the years 2022 and 2023. vii. Options to purchase 160,000 shares of Common Stock to four staff members, at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 17, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $23,000. viii. Options to purchase 200,000 shares of Common Stock to six staff members at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $26,000, and will be recognized during the years 2022 and 2023. ix. Options to purchase 40,000 shares of Common Stock to two consultants at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $5,000, and will be recognized during the years 2022 and 2023. x. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of $0.11 per share. The options vested upon grant and are exercisable through April 1, 2032. The fair value of the options at the date of grant amounted to approximately $2,000. xi. Options to purchase 3,210,000 shares of Common Stock to five senior officers, two consultants and ten staff members at an exercise price of $0.15 per share. The options vest on April 15, 2023 (in one year) and are exercisable through April 15, 2032. The fair value of the options at the date of grant amounted to approximately $394,000, and will be recognized during the years 2022 and 2023. xii. Options to purchase 1,090,000 shares of Common Stock to one senior officer, one board member and five staff members at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through April 15, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $149,000. xiii. Options to purchase 3,200,000 shares of Common Stock to eight board members at an exercise price of $0.15 per share. The options vest on April 15, 2023 (in one year) and are exercisable through April 15, 2023. The fair value of the options at the date of grant amounted to approximately $393,000. During the six months ended June 30, 2021, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 25,000 shares of Common Stock to one board member at an exercise price of $0.29 per share. The options vested upon grant and are exercisable through June 15, 2031. The fair value of the options at the date of grant amounted to approximately $6,000. C. Stock Options The stock option transactions since January 1, 2022 are shown in the table below: Number of Weighted Average US$ Outstanding, December 31, 2021 9,741,750 0.64 Changes during 2022 to: Granted to employees, officers, directors and others 11,625,000 0.13 Expired/Cancelled/Forfeited (610,000 ) 0.83 Exercised (105,000 ) 0.01 Outstanding, June 30, 2022 20,651,750 0.35 Exercisable, June 30, 2022 11,001,750 0.53 The following table summarizes information about stock options outstanding as of June 30, 2022: Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number Weighted Weighted Range of Number Weighted Weighted US$ US$ US$ US$ 0.14 240,000 9.56 0.14 0.01 10,000 1.37 0.01 0.15 3,000,000 9.52 0.15 0.01 5,000 1.95 0.01 0.15 6,410,000 9.80 0.15 0.01 20,000 3.92 0.01 — — — — 0.01 130,000 4.50 0.01 — — — — 0.01 50,000 4.51 0.01 — — — — 0.01 60,000 4.79 0.01 — — — — 0.01 200,000 4.88 0.01 — — — — 0.01 40,000 5.25 0.01 — — — — 0.01 70,000 5.50 0.01 — — — — 0.01 25,000 5.51 0.01 — — — — 0.01 30,000 5.66 0.01 — — — — 0.01 4,000 5.76 0.01 — — — — 0.01 25,000 6.52 0.01 — — — — 0.01 35,000 7.21 0.01 — — — — 0.01 150,000 7.38 0.01 — — — — 0.01 35,000 7.51 0.01 — — — — 0.01 75,000 8.51 0.01 — — — — 0.01 200,000 8.89 0.01 — — — — 0.01 335,000 9.04 0.01 — — — — 0.01 10,000 9.17 0.01 — — — — 0.01 500,000 9.51 0.01 — — — — 0.01 110,000 9.55 0.01 — — — — 0.01 1,090,000 9.79 0.01 — — — — 0.15 200,000 9.51 0.15 — — — — 0.15 25,000 9.75 0.15 — — — — 0.16 340,000 3.44 0.16 — — — — 0.16 75,000 7.44 0.16 — — — — 0.18 25,000 3.42 0.18 — — — — 0.25 50,000 9.17 0.25 — — — — 0.25 363,000 9.17 0.25 — — — — 0.28 25,000 3.17 0.28 — — — — 0.28 25,000 7.17 0.28 — — — — 0.29 25,000 4.95 0.29 — — — — 0.39 1,435,000 9.02 0.39 — — — — 0.59 1,400,000 4.88 0.59 — — — — 0.59 1,600,000 8.89 0.59 — — — — 0.92 350,000 4.51 0.92 — — — — 0.92 600,000 8.51 0.92 — — — — 1.33 25,000 0.83 1.33 — — — — 1.38 105,307 2.51 1.38 — — — — 1.67 405,943 2.26 1.67 — — — — 1.70 218,500 0.47 1.70 — — — — 1.75 250,000 1.02 1.75 — — — — 1.78 25,000 2.18 1.78 — — — — 2.31 250,000 1.51 2.31 — — — — 4.15 25,000 2.01 4.15 0.14-0.15 9,650,000 0.15 0.01-4.15 11,001,750 0.53 Granted to employees The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the six months ended 2022 2021 Weighted-average fair value of underlying stock at grant date $0.14 $0.67 Dividend yields — — Expected volatility 127%-135 % 120%-143% Risk-free interest rates 1.37%-2.79 % 0.16%-0.84% Expected lives (in years) 5.00-5.50 3.00-5.00 Weighted-average grant date fair value $0.13 $0.55 Granted to non-employees The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the six months ended 2022 2021 Weighted-average fair value of underlying stock at grant date $0.14 $0.59 Dividend yields — — Expected volatility 103% - 104% 113% Risk-free interest rates 1.78% - 2.83% 1.07% Expected lives (in years) 10 6.00 Weighted-average grant date fair value $0.13 $0.50 The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options. The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 (“SAB 110”), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life. D. Compensation Cost for Warrant and Option Issuances The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors: For the three months ended June 30, 2022 2021 US$ thousands US$ thousands 417 1,669 For the six months ended June 30, 2022 2021 US$ thousands US$ thousands 631 2,490 The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees: For the three months ended June 30, 2022 2021 US$ thousands US$ thousands 3 — For the six months ended June 30, 2022 2021 US$ thousands US$ thousands 4 99 The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: For the three months ended June 30, 2022 2021 US$ thousands US$ thousands 10 — For the six months ended June 30, 2022 2021 US$ thousands US$ thousands 17 — As of June 30, 2022, there was $843,000 of unrecognized compensation cost, related to non-vested stock options granted under the Company’s various stock option plans. That cost is expected to be recognized during the remaining periods of 2022 and 2023. E. Dividend Reinvestment and Stock Purchase Plan (“DSPP”) On March 13, 2014 Zion filed a registration statement on Form S-3 that is part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336. On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the “DSPP”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended. The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00. As of May 2, 2017, any outstanding ZNWAB warrants expired. As of May 2, 2018, any outstanding ZNWAC warrants expired. On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.” The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advanced notice to the warrant holders. On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.” All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017. Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.” The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2023 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.” The warrants became exercisable on April 19, 2018 and continued to be exercisable through April 19, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 19, 2019 to April 19, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 19, 2020 to April 19, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 19, 2021 to April 19, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.” The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.” The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.” The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continued to be exercisable through July 15, 2022 at a per share exercise price of $1.00. On March 21, 2022, the Company extended the termination date of the ZNWAM Warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” The warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00. On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this

Unproved Oil and Gas Properties

Unproved Oil and Gas Properties, Full Cost Method	6 Months Ended
	Jun. 30, 2022
Oil and Gas Property [Abstract]
Unproved Oil and Gas Properties, Full Cost Method	Note 4 - Unproved Oil and Gas Properties, Full Cost Method Unproved oil and gas properties, under the full cost method, are comprised as follows: June 30, December 31, US$ thousands US$ thousands Excluded from amortization base: Drilling costs, and other operational related costs 37,438 32,075 Capitalized salary costs 2,279 2,158 Capitalized interest costs 1,418 1,418 Legal and seismic costs, license fees and other preparation costs 12,076 11,260 Other costs 39 39 53,250 46,950 Changes in Unproved oil and gas properties during the three and six months ended June 30, 2022 and 2021 are as follows: For the three months ended For the six months ended 2022 2021 2022 2021 US$ thousands US$ thousands US$ thousands US$ thousands Excluded from amortization base: Drilling costs, and other operational related costs 4,735 7,590 5,363 14,592 Capitalized salary costs 69 56 121 117 Capitalized interest costs - 25 - 104 Legal costs, license fees and other preparation costs 347 728 816 1,762 Other costs - - - - *5,151 *8,399 *6,300 *16,575 * Inclusive of non-cash amounts of approximately $571,000, and $460,000 during the three months ended June 30, 2022, and 2021, respectively * Inclusive of non-cash amounts of approximately $1,708,000, and $2,902,000 during the six months ended June 30, 2022, and 2021, respectively Please refer to Footnote 1 – Nature of Operations and Going Concern for more information about Zion’s exploration activities.

Right of Use Lease Assets and L

Right of Use Lease Assets and Lease Obligations	6 Months Ended
	Jun. 30, 2022
Disclosure Text Block [Abstract]
Right of use lease assets and lease obligations	Note 5 - Right of use lease assets and lease obligations The Company is a lessee in several non-cancellable operating leases, primarily for transportation and office spaces. The table below presents the operating lease assets and liabilities recognized on the balance sheets as of June 30, 2022 and December 31, 2021: June 30, December 31, US$ US$ Operating lease assets $ 335 $ 327 Operating lease liabilities: Current operating lease liabilities $ 261 $ 203 Non-current operating lease liabilities $ 83 $ 169 Total operating lease liabilities $ 344 $ 372 The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of June 30, 2022 are: June 30, Weighted average remaining lease term (years) 1.33 Weighted average discount rate 3.7 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of June 30, 2022: US$ thousands 2022 140 2023 201 2024 12 2025 - 2026 - Thereafter - Total undiscounted future minimum lease payments 353 Less: portion representing imputed interest (9 ) Total undiscounted future minimum lease payments 344 Operating lease costs were $68,000 and $137,000 for the three and six months ended June 30, 2022, respectively. Operating lease costs were $65,000 and $128,000 for the three and six months ended June 30, 2021, respectively. Operating lease costs are included within general and administrative expenses on the statements of income. Cash paid for amounts included in the measurement of operating lease liabilities was $71,000 and $143,000 for the three and six months ended June 30, 2022, respectively. Cash paid for amounts included in the measurement of operating lease liabilities were $71,000 and $143,000 for the three and six months ended June 30, 2021. These amounts are included in operating activities in the statements of cash flows. Right-of-use assets obtained in exchange for new operating lease liabilities were $136,000 and $136,000 for the three and six months ended June 30, 2022, respectively. Right-of-use assets obtained in exchange for new operating lease liabilities were $128,000 and $128,000 for the three and six months ended June 30, 2021, respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 6 - Commitments and Contingencies A. Securities and Exchange Commission (“SEC”) Investigation As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation. Since that date, we have fully cooperated with the SEC on an on-going basis in connection with its investigation. Investigations of this nature are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, an SEC investigation could have an adverse impact on us because of legal costs, diversion of management resources, and other factors. The investigation could also result in reputational harm to Zion and may have a material adverse effect on Zion’s current and future business and exploratory activities and its ability to raise capital to continue our oil and gas exploratory activities. B. Litigation From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. The Company is not subject to any litigation at the present time. C. Recent Market Conditions – Coronavirus Pandemic During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic has significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments react to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. As of the date of this report, many of our employees are working from home. However, while there are various uncertainties to navigate, the Company’s business activities are continuing. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. We cannot predict whether, when or the manner in which the conditions surrounding COVID-19 will change including the timing of lifting any restrictions or work from home arrangements. The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others. D. Environmental and Onshore Licensing Regulatory Matters The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings. The Company believes that these regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells. As of June 30, 2022, and December 31, 2021, the Company accrued $ nil nil E. Bank Guarantees As of June 30, 2022, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately $1,218,000) and others (approximately $63,000) with respect to its drilling operation in an aggregate amount of approximately $1,281,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts and are reported on the Company’s balance sheets as fixed short-term bank deposits – restricted. F. Risks Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates. Foreign Currency Exchange Rate Risks. Interest Rate Risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 7 - Subsequent Events (i) Approximately $533,000 was collected through the Company’s DSPP program during the period July 1 through August 8, 2022. (ii) Options to purchase 25,000 shares of Common Stock to one board member at an exercise price of $0.235 per share. The options vested upon grant and are exercisable through August 1, 2032. The fair value of the options at the date of grant amounted to approximately $5,875.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Net Gain (Loss) per Share Data	A. Net Gain (Loss) per Share Data Basic and diluted net (loss) gain per share of common stock, par value $0.01 per share (“Common Stock”), is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share, as the inclusion of 37,061,435 and 34,216,856 and 16,426,527 and 15,248,643 Common Stock equivalents in the three and six-month period ended June 30, 2022 and 2021 respectively, would be anti-dilutive.
Use of Estimates	B. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.
Oil and Gas Properties and Impairment	C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the three and six months ended June 30, 2022, and 2021, respectively, the Company did not record any post-impairment charges. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $53,250,000 and $46,950,000 as of June 30, 2022 and December 31, 2021, respectively.
Fair Value Measurements	D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At June 30, 2022, and December 31, 2021, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. Derivative instruments are carried at fair value, generally estimated using the Binomial Model.
Stock-Based Compensation	E. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
Warrants	F. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period, or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity
Related parties	G. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report.
Recently Adopted Accounting Pronouncements	H. Recently Adopted Accounting Pronouncements ASU 2016-02 – Leases (Topic 842) In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”) in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. Zion adopted ASU 2016-02 in the first quarter of 2019. Presently, Zion has operating leases for office space in Dallas, Texas and in Caesarea, Israel plus various leases for motor vehicles. These leases have been accounted for under ASU 2016-02 in 2020, 2021 and 2022 by establishing a right-of-use asset and a corresponding current lease liability and non-current lease liability. Zion is not subject to any loan covenants and therefore, the increase in assets and liabilities does not have a material impact on its business. ASU 2020-03, “Codification Improvements to Financial Instruments” In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its consolidated financial statements. In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company does not believe that this ASU will have any impact on its consolidated financial statements. The Company does not believe that the adoption of any of the recently issued accounting pronouncements had a significant impact on our consolidated financial position, results of operations, or cash flow, except for ASC Update No. 2016-02—Leases, which requires organizations to recognize lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP. See Note 5 for more complete details on balances at June 30, 2022 and December 31, 2021. It is the Company’s practice to review any newly established Accounting Standard Updates with each reporting period. As of June 30, 2022, and through the filing date of this report, no recently issued updates have been found applicable to have a material effect on the Company’s financial statements.
Depreciation and Accounting for Drilling Rig and Related Equipment	I. Depreciation and Accounting for Drilling Rig and Related Equipment On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. We remitted to the Seller $250,000 on February 6, 2020 as earnest money towards the purchase price. The Closing anticipated by the Agreement took place on March 12, 2020 by the Seller’s execution and delivery of a Bill of Sale to us. On March 13, 2020, the Seller retained the earnest money deposit, and the Company remitted $4,350,000 to the seller towards the purchase price and $1,000,000 (the “Holdback Amount”) was deposited in escrow with American Stock Transfer and Trust Company LLC, as escrow agent, through November 30, 2020, or as extended by mutual agreement of the parties, pending a determination, if any, by us of any operating deficiency in the drilling rig. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021. Since the rig purchase closed during March 2020, it was recorded on Zion’s books as a long-term fixed asset as a component of Property and Equipment. The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion will depreciate the rig on a straight-line basis. The $540,000 in spare parts was the original cost to CED. These items were received and counted by Zion upon receipt. All records and files are maintained by Zion. Zion plans to obtain a physical count of the equipment items at the end of each quarter, or as close to such date as practical, in accordance with our normal procedures. Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly. See the table below for a reconciliation of the rig-related activity during the six months ended June 30, 2022: I-35 Drilling Rig & Associated Equipment: Six-month period ended June 30, 2022 I-35 Rig Other Total US$ US$ US$ US$ December 31, 2021 5,859 642 333 6,834 Asset Additions - 135 211 346 Asset Depreciation (317 ) - (54 ) (371 ) Asset Disposals for Self-Consumption - (171 ) - (171 ) June 30, 2022 5,542 606 490 6,638

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of drilling rig & associated equipment	Six-month period ended June 30, 2022 I-35 Rig Other Total US$ US$ US$ US$ December 31, 2021 5,859 642 333 6,834 Asset Additions - 135 211 346 Asset Depreciation (317 ) - (54 ) (371 ) Asset Disposals for Self-Consumption - (171 ) - (171 ) June 30, 2022 5,542 606 490 6,638

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity (Tables) [Line Items]
Schedule of stock option transactions	Number of Weighted Average US$ Outstanding, December 31, 2021 9,741,750 0.64 Changes during 2022 to: Granted to employees, officers, directors and others 11,625,000 0.13 Expired/Cancelled/Forfeited (610,000 ) 0.83 Exercised (105,000 ) 0.01 Outstanding, June 30, 2022 20,651,750 0.35 Exercisable, June 30, 2022 11,001,750 0.53
Schedule of stock options outstanding	Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number Weighted Weighted Range of Number Weighted Weighted US$ US$ US$ US$ 0.14 240,000 9.56 0.14 0.01 10,000 1.37 0.01 0.15 3,000,000 9.52 0.15 0.01 5,000 1.95 0.01 0.15 6,410,000 9.80 0.15 0.01 20,000 3.92 0.01 — — — — 0.01 130,000 4.50 0.01 — — — — 0.01 50,000 4.51 0.01 — — — — 0.01 60,000 4.79 0.01 — — — — 0.01 200,000 4.88 0.01 — — — — 0.01 40,000 5.25 0.01 — — — — 0.01 70,000 5.50 0.01 — — — — 0.01 25,000 5.51 0.01 — — — — 0.01 30,000 5.66 0.01 — — — — 0.01 4,000 5.76 0.01 — — — — 0.01 25,000 6.52 0.01 — — — — 0.01 35,000 7.21 0.01 — — — — 0.01 150,000 7.38 0.01 — — — — 0.01 35,000 7.51 0.01 — — — — 0.01 75,000 8.51 0.01 — — — — 0.01 200,000 8.89 0.01 — — — — 0.01 335,000 9.04 0.01 — — — — 0.01 10,000 9.17 0.01 — — — — 0.01 500,000 9.51 0.01 — — — — 0.01 110,000 9.55 0.01 — — — — 0.01 1,090,000 9.79 0.01 — — — — 0.15 200,000 9.51 0.15 — — — — 0.15 25,000 9.75 0.15 — — — — 0.16 340,000 3.44 0.16 — — — — 0.16 75,000 7.44 0.16 — — — — 0.18 25,000 3.42 0.18 — — — — 0.25 50,000 9.17 0.25 — — — — 0.25 363,000 9.17 0.25 — — — — 0.28 25,000 3.17 0.28 — — — — 0.28 25,000 7.17 0.28 — — — — 0.29 25,000 4.95 0.29 — — — — 0.39 1,435,000 9.02 0.39 — — — — 0.59 1,400,000 4.88 0.59 — — — — 0.59 1,600,000 8.89 0.59 — — — — 0.92 350,000 4.51 0.92 — — — — 0.92 600,000 8.51 0.92 — — — — 1.33 25,000 0.83 1.33 — — — — 1.38 105,307 2.51 1.38 — — — — 1.67 405,943 2.26 1.67 — — — — 1.70 218,500 0.47 1.70 — — — — 1.75 250,000 1.02 1.75 — — — — 1.78 25,000 2.18 1.78 — — — — 2.31 250,000 1.51 2.31 — — — — 4.15 25,000 2.01 4.15 0.14-0.15 9,650,000 0.15 0.01-4.15 11,001,750 0.53
Schedule of compensation cost of warrant and option issuances	For the three months ended June 30, 2022 2021 US$ thousands US$ thousands 417 1,669 For the six months ended June 30, 2022 2021 US$ thousands US$ thousands 631 2,490 For the three months ended June 30, 2022 2021 US$ thousands US$ thousands 3 — For the six months ended June 30, 2022 2021 US$ thousands US$ thousands 4 99 For the three months ended June 30, 2022 2021 US$ thousands US$ thousands 10 — For the six months ended June 30, 2022 2021 US$ thousands US$ thousands 17 —
Schedule of warrants transactions	Warrants Exercise Warrant Outstanding Balance, 12/31/2021 Warrants Warrants Warrants Outstanding Balance, 06/30/2022 ZNWAA $ 2.00 01/31/2023 1,498,804 - - - 1,498,804 ZNWAD $ 1.00 05/02/2023 243,853 - - - 243,853 ZNWAE $ 1.00 05/01/2023 2,144,099 - - - 2,144,099 ZNWAF $ 1.00 08/14/2023 359,435 - - - 359,435 ZNWAG $ 1.00 01/08/2023 240,068 - - - 240,068 ZNWAH $ 5.00 04/19/2023 372,400 - - - 372,400 ZNWAI $ 3.00 06/29/2023 640,710 - - 640,710 ZNWAJ $ 1.00 10/29/2023 545,900 - - - 545,900 ZNWAK $ 0.01 02/25/2023 431,675 - (6,650 ) - 425,025 ZNWAL $ 2.00 08/26/2023 517,875 - - - 517,875 ZNWAM $ 1.00 07/15/2023 4,376,000 - - - 4,376,000 ZNWAN $ 1.00 05/16/2023 267,660 100 - - 267,760 ZNWAO $ 0.25 06/12/2023 174,970 - (310 ) - 174,660 ZNWAQ $ 0.25 07/06/2023 - 23,428,348 - - 23,428,348 ZNWAP $ 0.25 06/02/2023 439,916 - (439,916 ) - - ZNWAR $ 0.25 06/23/2023 1,020,000 - (1,020,000 ) - - Outstanding warrants 13,273,365 23,428,448 (1,466,776 ) - 35,234,937
Schedule of warrants to investors	Period of Grant US$ Expiration Date ZNWAA Warrants B,C March 2013 – December 2014 2.00 January 31, 2023 ZNWAD Warrants A,B,C January 2015 – March 2016 1.00 May 02, 2023 ZNWAE Warrants B,C November 2016 – March 2017 1.00 May 01, 2023 ZNWAF Warrants A,B,C May 2017 – July 2017 1.00 August 14, 2023 ZNWAG Warrants C October 2017 – December 2017 1.00 January 08, 2023 ZNWAH Warrants A,B,C February 2018 5.00 April 19, 2023 ZNWAI Warrants A,B,C April 2018 – May 2018 3.00 June 29, 2023 ZNWAJ Warrants B,C August 2018 – September 2018 1.00 October 29, 2023 ZNWAK Warrants B,C December 2018 – January 2019 0.01 February 25, 2023 ZNWAL Warrants C July 2019 – August 2019 2.00 August 26, 2023 ZNWAM Warrants D January 2021 – March 2021 1.00 July 15, 2023 ZNWAN Warrants May – June 2021 1.00 May 16, 2023 ZNWAO Warrants June 2021 0.25 June 12, 2023 ZNWAQ Warrants E June 2021 0.25 July 6, 2023 ZNWAS Warrants F August 2021 – March 2022 0.25 December 31, 2023
Employees [Member]
Stockholders' Equity (Tables) [Line Items]
Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model	For the six months ended 2022 2021 Weighted-average fair value of underlying stock at grant date $0.14 $0.67 Dividend yields — — Expected volatility 127%-135 % 120%-143% Risk-free interest rates 1.37%-2.79 % 0.16%-0.84% Expected lives (in years) 5.00-5.50 3.00-5.00 Weighted-average grant date fair value $0.13 $0.55 For the six months ended 2022 2021 Weighted-average fair value of underlying stock at grant date $0.14 $0.59 Dividend yields — — Expected volatility 103% - 104% 113% Risk-free interest rates 1.78% - 2.83% 1.07% Expected lives (in years) 10 6.00 Weighted-average grant date fair value $0.13 $0.50

Unproved Oil and Gas Properti_2

Unproved Oil and Gas Properties, Full Cost Method (Tables)	6 Months Ended
	Jun. 30, 2022
Oil and Gas Property [Abstract]
Schedule of unproved oil and gas properties	June 30, December 31, US$ thousands US$ thousands Excluded from amortization base: Drilling costs, and other operational related costs 37,438 32,075 Capitalized salary costs 2,279 2,158 Capitalized interest costs 1,418 1,418 Legal and seismic costs, license fees and other preparation costs 12,076 11,260 Other costs 39 39 53,250 46,950
Schedule of changes in Unproved oil and gas properties	For the three months ended For the six months ended 2022 2021 2022 2021 US$ thousands US$ thousands US$ thousands US$ thousands Excluded from amortization base: Drilling costs, and other operational related costs 4,735 7,590 5,363 14,592 Capitalized salary costs 69 56 121 117 Capitalized interest costs - 25 - 104 Legal costs, license fees and other preparation costs 347 728 816 1,762 Other costs - - - - *5,151 *8,399 *6,300 *16,575 * Inclusive of non-cash amounts of approximately $571,000, and $460,000 during the three months ended June 30, 2022, and 2021, respectively * Inclusive of non-cash amounts of approximately $1,708,000, and $2,902,000 during the six months ended June 30, 2022, and 2021, respectively

Right of Use Lease Assets and_2

Right of Use Lease Assets and Lease Obligations (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Text Block [Abstract]
Schedule of operating lease assets and liabilities	June 30, December 31, US$ US$ Operating lease assets $ 335 $ 327 Operating lease liabilities: Current operating lease liabilities $ 261 $ 203 Non-current operating lease liabilities $ 83 $ 169 Total operating lease liabilities $ 344 $ 372
Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	June 30, Weighted average remaining lease term (years) 1.33 Weighted average discount rate 3.7 %
Schedule of future minimum lease payments under non-cancellable operating leases	US$ thousands 2022 140 2023 201 2024 12 2025 - 2026 - Thereafter - Total undiscounted future minimum lease payments 353 Less: portion representing imputed interest (9 ) Total undiscounted future minimum lease payments 344

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Going Concern (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Net loss	$ 4.8
Accumulated deficit	$ 228.3
Megiddo Jezreel License [Member]
Nature of Operations, Basis of Presentation and Going Concern (Details) [Line Items]
Area of land depth, description	On November 23, 2021, Zion announced via a press release that it completed drilling the MJ-02 well to a total depth of 5,531 meters (~18,141 feet) with a 6 inch open hole at that depth.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 13, 2020	Feb. 06, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Mar. 12, 2020	Apr. 13, 2018
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock, par value (in Dollars per share)				$ 0.01		$ 0.01		$ 0.01		$ 0.01
Common stock equivalents excluded from EPS as the inclusion would be anti-dilutive (in Shares) (in Shares)				37,061,435	34,216,856
Common stock equivalents (in Shares)						16,426,527	15,248,643
Capitalized exploration costs						$ 53,250,000		$ 46,950,000
Remaining amount held in escrow deposit			$ 250,000
Purchase price		$ 4,350,000
Escrow deposit		$ 1,000,000
Purchase price of drilling ring	$ 5,600,000
Consumable inventory included in the rig purchase	540,000
Spare parts inventory	$ 48,000
Useful life of drilling rig						10 years
Purchase and Sale Agreement [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Equipment and excess inventory									$ 5,600,000
Spare parts inventory				$ 540,000		$ 540,000
Useful life of drilling rig						5 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	$ 6,834
Asset Additions	346
Asset Depreciation	(371)
Asset Disposals for Self-Consumption	(171)
Balance ending	6,638
I-35 Drilling Rig [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	5,859
Asset Additions
Asset Depreciation	(317)
Asset Disposals for Self-Consumption
Balance ending	5,542
Rig Spare Parts [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	642
Asset Additions	135
Asset Depreciation
Asset Disposals for Self-Consumption	(171)
Balance ending	606
Other Drilling Assets [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	333
Asset Additions	211
Asset Depreciation	(54)
Asset Disposals for Self-Consumption
Balance ending	$ 490

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
		Apr. 13, 2018	Aug. 08, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jun. 29, 2020
Stockholders' Equity (Details) [Line Items]
Common stock, par value		$ 0.01		$ 0.01		$ 0.01		$ 0.01
Fair value of stock options granted							$ 6,000
Option to purchase shares of common stock					25,000		25,000
Exercise price per share					$ 0.29		$ 0.29
Unrecognized compensation cost						$ 843,000
Exercise price per share						$ 0.25
DSPP program raised amount				$ 1,566,000	$ 10,939,000	$ 12,993,000	$ 13,788,000
Subscription price per share		5
Price per share		$ 3							$ 3
2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Stock option plan, expiration date						The options vested upon grant and are exercisable through January 4, 2032.
Shares of common stock						38,000,000
Exercisable period						10 years
Dividend Reinvestment and Stock Purchase Plan [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description						The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00.
ZNWAB warrants [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description						As of May 2, 2017, any outstanding ZNWAB warrants expired.
ZNWAC warrants [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description						As of May 2, 2018, any outstanding ZNWAC warrants expired.
ZNWAI Warrants [Member]
Stockholders' Equity (Details) [Line Items]
Price per share	[1],[2],[3]			$ 3		$ 3
ZNWAD Warrant Two [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description						On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.” The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advanced notice to the warrant holders. On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.” All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017. Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.”  The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2023 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.” The warrants became exercisable on April 19, 2018 and continued to be exercisable through April 19, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 19, 2019 to April 19, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 19, 2020 to April 19, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 19, 2021 to April 19, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.” The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.” The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.” The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continued to be exercisable through July 15, 2022 at a per share exercise price of $1.00. On March 21, 2022, the Company extended the termination date of the ZNWAM Warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” The warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00. On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.” The warrants became exercisable on June 12, 2021 and continue to be exercisable through June 12, 2023 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of units of shares and warrants to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continued to be exercisable through June 2, 2022 at a per share exercise price of $.25. On March 21, 2022, the Company extended the termination date of the ZNWAP Warrant by one (1) year from the expiration date of June 2, 2022 to June 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. During the second quarter of 2022, all warrants represented by ZNWAP and ZNWAR were exercised resulting in a net cash inflow of $364,979. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and are exercisable through July 6, 2022 at a per share exercise price of $.25. On May 17, 2022, the Company extended the termination date of the ZNWAQ Warrant by one (1) year from the expiration date of July 6, 2022 to July 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program. On March 21, 2022, the Company extended the termination date of the ZNWAR Warrant by one (1) year from the expiration date of June 22, 2022 to June 22, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. During the second quarter of 2022, all warrants represented by ZNWAP and ZNWAR were exercised resulting in a net cash inflow of $364,979. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account will be credited with the number of shares of the Company’s Common Stock and Warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be exercisable on November 15, 2023 and continue to be exercisable through December 31, 2023 at a per share exercise price of $.25. During 2021, two participants who participated in the “Request for Waiver” aspect of the DSPP contributed approximately 67% of the cash raised through the DSPP. During the six months ended June 30, 2022, one participant in the “Request for Waiver” aspect of the DSPP contributed approximately 77% of the cash raised through the DSPP. On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein. On December 10, 2021 Zion filed an Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-235299) for the purpose of converting the existing Form S-1 to the Registration Statement on Form S-3. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly such prospectus has not been included herein. For the three and six months ended June 30, 2022, approximately $1,566,000, and $12,993,000 were raised under the DSPP program, respectively. For the three and six months ended June 30, 2021, approximately $10,939,000, and $13,788,000 were raised under the DSPP program, respectively. The company raised approximately $533,000 from the period July 1, 2022 through August 8, 2022, under the DSPP program. The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only. F. Subscription Rights Offering  On April 2, 2018 the Company announced an offering (“2018 Subscription Rights Offering”) through American Stock Transfer & Trust Company, LLC (the “Subscription Agent”), at no cost to the shareholders, of non-transferable Subscription Rights (each “Right” and collectively, the “Rights”) to purchase its securities to persons who owned shares of our Common Stock on April 13, 2018 (“the Record Date”). Pursuant to the 2018 Subscription Rights Offering, each holder of shares of common stock on the Record Date received non-transferable Subscription Rights, with each Right comprised of one share of the Company Common Stock, par value $0.01 per share (the “Common Stock”) and one Common Stock Purchase Warrant to purchase an additional one share of Common Stock. Each Right could be exercised or subscribed at a per Right subscription price of $5.00. Each Warrant affords the investor the opportunity to purchase one share of the Company Common Stock at a warrant exercise price of $3.00. The warrant is referred to as “ZNWAI.” The warrants became exercisable on June 29, 2018 and continued to be exercisable through June 29, 2020 at a per share exercise price of $3.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of June 29, 2019 to June 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAI Warrant by one (1) year from the expiration date of June 29, 2020 to June 29, 2021. On September 15, 2020, the Company extended the termination date of the ZNWAI Warrant by two (2) years from the expiration date of June 29, 2021 to June 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Each shareholder received .10 (one tenth) of a Subscription Right (i.e. one Subscription Right for each 10 shares owned) for each share of the Company’s Common Stock owned on the Record Date. The 2018 Subscription Rights Offering terminated on May 31, 2018. The Company raised net proceeds of approximately $3,038,000, from the subscription of Rights, after deducting fees and expenses of $243,000 incurred in connection with the rights offering.
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Warrant exercise price						$ 0.25
Subscription Rights Offering [Member]
Stockholders' Equity (Details) [Line Items]
Proceeds from the sale of the rights						$ 3,038,000
Expenses from offering						$ 243,000
Znwaf [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, par value				$ 5		$ 5
Subsequent Event [Member]
Stockholders' Equity (Details) [Line Items]
DSPP program raised amount			$ 533,000
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Subscription rights offering, description						On September 15, 2020, the Company extended the termination date of the ZNWAI Warrant by two (2) years from the expiration date of June 29, 2021 to June 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.
Warrant [Member] | ZNWAI Warrants [Member]
Stockholders' Equity (Details) [Line Items]
Expiration date, description						On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021.
Six Senior Officers [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan							600,000
Exercise price per unit					$ 0.915		$ 0.915
Stock option plan, expiration date						The options vested upon grant and are exercisable through January 4, 2031.
Fair value of stock options granted						$ 456,000
Six Senior Officers [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 22,000
Option to purchase shares of common stock				175,000		175,000
Exercise price per share				$ 0.1529		$ 0.1529
One senior officer [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit					0.01		0.01
Stock option plan, expiration date						The options vested upon grant and are exercisable through January 6, 2031.
Fair value of stock options granted						$ 68,000
Shares purchased under option plan						75,000
One senior officer [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 39,000
Option to purchase shares of common stock				25,000		25,000
Exercise price per share				$ 0.01		$ 0.01
One senior officer [Member] | 2021 Omnibus Incentive Stock Option Plan [Member] | Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Option to purchase shares of common stock				300,000		300,000
Six Senior Officers And Three Staff [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan						1,800,000
Exercise price per unit					0.59		0.59
Stock option plan, expiration date						The options vested upon grant and are exercisable through May 21, 2031.
Fair value of stock options granted						$ 885,000
One Senior Officer One [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan						200,000
Exercise price per unit					0.01		$ 0.01
Fair value of stock options granted						$ 117,000
Seven Board [Member] | 2011 Non-Employee Directors Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan							350,000
Exercise price per unit					0.915		$ 0.915
Stock option plan, expiration date						The options vested upon grant and are exercisable through January 4, 2027.
Fair value of stock options granted							$ 252,000
Seven Board [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Stock option plan, expiration date						The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032.
Fair value of stock options granted						$ 182,000
Option to purchase shares of common stock				1,400,000		1,400,000
Exercise price per share				$ 0.1529		$ 0.1529
One Board [Member] | 2011 Non-Employee Directors Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan							50,000
Exercise price per unit					0.01		$ 0.01
Fair value of stock options granted						$ 45,000
One Board [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 2,000
Option to purchase shares of common stock				25,000		25,000
Exercise price per share				$ 0.11		$ 0.11
Six Board [Member] | 2011 Non-Employee Directors Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan						1,400,000
Exercise price per unit					0.59		$ 0.59
Fair value of stock options granted							$ 643,000
One Board One [Member] | 2011 Non-Employee Directors Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan							200,000
Exercise price per unit					$ 0.01		$ 0.01
Fair value of stock options granted							$ 116,000
One Board One [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 29,000
Option to purchase shares of common stock				200,000		200,000
Exercise price per share				$ 0.01		$ 0.01
Seven Staff [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 4,000
Five Senior Officers And Four Staff [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 209,000
Option to purchase shares of common stock				1,600,000		1,600,000
Exercise price per share				$ 0.1529		$ 0.1529
Warrants and Options [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Stock option plan, expiration date						The options vested upon grant and are exercisable through January 17, 2032
Fair value of stock options granted						$ 23,000
Option to purchase shares of common stock				160,000		160,000
Exercise price per share				$ 0.01		$ 0.01
Six Staff [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 26,000
Option to purchase shares of common stock				200,000		200,000
Exercise price per share				$ 0.14		$ 0.14
Two Consultants [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 5,000
Option to purchase shares of common stock				40,000		40,000
Exercise price per share				$ 0.14		$ 0.14
Five senior officer [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 394,000
Option to purchase shares of common stock				3,210,000		3,210,000
Exercise price per share				$ 0.15		$ 0.15
One Senior Officer, One Board [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 149,000
Option to purchase shares of common stock				1,090,000		1,090,000
Exercise price per share				$ 0.01		$ 0.01
Eight Board [Member] | 2021 Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted						$ 393,000
Option to purchase shares of common stock				3,200,000		3,200,000
Exercise price per share				$ 0.15		$ 0.15
New Unit Program [Member] | Znwaf [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit				$ 1		$ 1
Amended and Restated Certificate of Incorporation [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Increase in shares authorized				400,000,000		400,000,000
Amended and Restated Certificate of Incorporation [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Increase in shares authorized				800,000,000		800,000,000
ZNWAJ Warrant [Member]
Stockholders' Equity (Details) [Line Items]
New unit program, description						On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 19, 2020 to April 19, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 19, 2021 to April 19, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.” The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.” The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.” The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continued to be exercisable through July 15, 2022 at a per share exercise price of $1.00. On March 21, 2022, the Company extended the termination date of the ZNWAM Warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” The warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00. On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.” The warrants became exercisable on June 12, 2021 and continue to be exercisable through June 12, 2023 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of units of shares and warrants to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continued to be exercisable through June 2, 2022 at a per share exercise price of $.25. On March 21, 2022, the Company extended the termination date of the ZNWAP Warrant by one (1) year from the expiration date of June 2, 2022 to June 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. During the second quarter of 2022, all warrants represented by ZNWAP and ZNWAR were exercised resulting in a net cash inflow of $364,979. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and are exercisable through July 6, 2022 at a per share exercise price of $.25. On May 17, 2022, the Company extended the termination date of the ZNWAQ Warrant by one (1) year from the expiration date of July 6, 2022 to July 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program. On March 21, 2022, the Company extended the termination date of the ZNWAR Warrant by one (1) year from the expiration date of June 22, 2022 to June 22, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. During the second quarter of 2022, all warrants represented by ZNWAP and ZNWAR were exercised resulting in a net cash inflow of $364,979. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account will be credited with the number of shares of the Company’s Common Stock and Warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be exercisable on November 15, 2023 and continue to be exercisable through December 31, 2023 at a per share exercise price of $.25. During 2021, two participants who participated in the “Request for Waiver” aspect of the DSPP contributed approximately 67% of the cash raised through the DSPP. During the six months ended June 30, 2022, one participant in the “Request for Waiver” aspect of the DSPP contributed approximately 77% of the cash raised through the DSPP. On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein. On December 10, 2021 Zion filed an Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-235299) for the purpose of converting the existing Form S-1 to the Registration Statement on Form S-3. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly such prospectus has not been included herein. For the three and six months ended June 30, 2022, approximately $1,566,000, and $12,993,000 were raised under the DSPP program, respectively. For the three and six months ended June 30, 2021, approximately $10,939,000, and $13,788,000 were raised under the DSPP program, respectively. The company raised approximately $533,000 from the period July 1, 2022 through August 8, 2022, under the DSPP program. The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only. F. Subscription Rights Offering  On April 2, 2018 the Company announced an offering (“2018 Subscription Rights Offering”) through American Stock Transfer & Trust Company, LLC (the “Subscription Agent”), at no cost to the shareholders, of non-transferable Subscription Rights (each “Right” and collectively, the “Rights”) to purchase its securities to persons who owned shares of our Common Stock on April 13, 2018 (“the Record Date”). Pursuant to the 2018 Subscription Rights Offering, each holder of shares of common stock on the Record Date received non-transferable Subscription Rights, with each Right comprised of one share of the Company Common Stock, par value $0.01 per share (the “Common Stock”) and one Common Stock Purchase Warrant to purchase an additional one share of Common Stock. Each Right could be exercised or subscribed at a per Right subscription price of $5.00. Each Warrant affords the investor the opportunity to purchase one share of the Company Common Stock at a warrant exercise price of $3.00. The warrant is referred to as “ZNWAI.” The warrants became exercisable on June 29, 2018 and continued to be exercisable through June 29, 2020 at a per share exercise price of $3.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of June 29, 2019 to June 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAI Warrant by one (1) year from the expiration date of June 29, 2020 to June 29, 2021. On September 15, 2020, the Company extended the termination date of the ZNWAI Warrant by two (2) years from the expiration date of June 29, 2021 to June 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Each shareholder received .10 (one tenth) of a Subscription Right (i.e. one Subscription Right for each 10 shares owned) for each share of the Company’s Common Stock owned on the Record Date. The 2018 Subscription Rights Offering terminated on May 31, 2018. The Company raised net proceeds of approximately $3,038,000, from the subscription of Rights, after deducting fees and expenses of $243,000 incurred in connection with the rights offering.
[1]On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year.[2]On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.[3]On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of stock option transactions - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Stockholders' Equity (Details) - Schedule of stock option transactions [Line Items]
Number of shares, Outstanding, Beginning | shares	9,741,750
Weighted Average exercise price, Outstanding, Beginning | $ / shares	$ 0.64
Number of shares, Granted to employees, officers, directors and others | shares	11,625,000
Weighted Average exercise price, Granted to employees, officers, directors and others | $ / shares	$ 0.13
Number of shares, Expired/Cancelled/Forfeited | shares	(610,000)
Weighted Average exercise price, Expired/Cancelled/Forfeited | $ / shares	$ 0.83
Number of shares, Exercised | shares	(105,000)
Weighted Average exercise price, Exercised | $ / shares	$ 0.01
Number of shares, Outstanding, Ending | shares	20,651,750
Weighted Average exercise price, Outstanding, Ending | $ / shares	$ 0.35
Number of shares, Exercisable | shares	11,001,750
Weighted Average exercise price, Exercisable | $ / shares	$ 0.53

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of stock options outstanding	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares	9,650,000
Weighted Average Exercise price	$ 0.15
Non-vested [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.14
Non-vested [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.15
Non-vested [Member] | Ranges One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.14
Number outstanding (in Shares) | shares	240,000
Weighted average remaining contractual life (years)	9 years 6 months 21 days
Weighted Average Exercise price	$ 0.14
Non-vested [Member] | Ranges Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number outstanding (in Shares) | shares	3,000,000
Weighted average remaining contractual life (years)	9 years 6 months 7 days
Weighted Average Exercise price	$ 0.15
Non-vested [Member] | Ranges Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number outstanding (in Shares) | shares	6,410,000
Weighted average remaining contractual life (years)	9 years 9 months 18 days
Weighted Average Exercise price	$ 0.15
Non-vested [Member] | Ranges Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding (in Shares) | shares	11,001,750
Weighted Average Exercise price	$ 0.53
Vested [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.01
Vested [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	4.15
Vested [Member] | Ranges One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	1 year 4 months 13 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	5,000
Weighted average remaining contractual life (years)	1 year 11 months 12 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	20,000
Weighted average remaining contractual life (years)	3 years 11 months 1 day
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	130,000
Weighted average remaining contractual life (years)	4 years 6 months
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	4 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	60,000
Weighted average remaining contractual life (years)	4 years 9 months 14 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	4 years 10 months 17 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	40,000
Weighted average remaining contractual life (years)	5 years 3 months
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	70,000
Weighted average remaining contractual life (years)	5 years 6 months
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	5 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	30,000
Weighted average remaining contractual life (years)	5 years 7 months 28 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	4,000
Weighted average remaining contractual life (years)	5 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	6 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	7 years 2 months 15 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	150,000
Weighted average remaining contractual life (years)	7 years 4 months 17 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	7 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	8 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	8 years 10 months 20 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	335,000
Weighted average remaining contractual life (years)	9 years 14 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	9 years 2 months 1 day
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	500,000
Weighted average remaining contractual life (years)	9 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	110,000
Weighted average remaining contractual life (years)	9 years 6 months 18 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number outstanding (in Shares) | shares	1,090,000
Weighted average remaining contractual life (years)	9 years 9 months 14 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	9 years 6 months 3 days
Weighted Average Exercise price	$ 0.15
Vested [Member] | Ranges Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 9 months
Weighted Average Exercise price	$ 0.15
Vested [Member] | Ranges Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number outstanding (in Shares) | shares	340,000
Weighted average remaining contractual life (years)	3 years 5 months 8 days
Weighted Average Exercise price	$ 0.16
Vested [Member] | Ranges Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	7 years 5 months 8 days
Weighted Average Exercise price	$ 0.16
Vested [Member] | Ranges Twenty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 years 5 months 1 day
Weighted Average Exercise price	$ 0.18
Vested [Member] | Ranges Twenty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	9 years 2 months 1 day
Weighted Average Exercise price	$ 0.25
Vested [Member] | Ranges Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number outstanding (in Shares) | shares	363,000
Weighted average remaining contractual life (years)	9 years 2 months 1 day
Weighted Average Exercise price	$ 0.25
Vested [Member] | Ranges Thirty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 years 2 months 1 day
Weighted Average Exercise price	$ 0.28
Vested [Member] | Ranges Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	7 years 2 months 1 day
Weighted Average Exercise price	$ 0.28
Vested [Member] | Ranges Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.29
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	4 years 11 months 12 days
Weighted Average Exercise price	$ 0.29
Vested [Member] | Ranges Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.39
Number outstanding (in Shares) | shares	1,435,000
Weighted average remaining contractual life (years)	9 years 7 days
Weighted Average Exercise price	$ 0.39
Vested [Member] | Ranges Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number outstanding (in Shares) | shares	1,400,000
Weighted average remaining contractual life (years)	4 years 10 months 17 days
Weighted Average Exercise price	$ 0.59
Vested [Member] | Ranges Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number outstanding (in Shares) | shares	1,600,000
Weighted average remaining contractual life (years)	8 years 10 months 20 days
Weighted Average Exercise price	$ 0.59
Vested [Member] | Ranges Thirty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number outstanding (in Shares) | shares	350,000
Weighted average remaining contractual life (years)	4 years 6 months 3 days
Weighted Average Exercise price	$ 0.92
Vested [Member] | Ranges Thirty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number outstanding (in Shares) | shares	600,000
Weighted average remaining contractual life (years)	8 years 6 months 3 days
Weighted Average Exercise price	$ 0.92
Vested [Member] | Ranges Thirty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.33
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 months 29 days
Weighted Average Exercise price	$ 1.33
Vested [Member] | Ranges Fourty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.38
Number outstanding (in Shares) | shares	105,307
Weighted average remaining contractual life (years)	2 years 6 months 3 days
Weighted Average Exercise price	$ 1.38
Vested [Member] | Range Fourty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.67
Number outstanding (in Shares) | shares	405,943
Weighted average remaining contractual life (years)	2 years 3 months 3 days
Weighted Average Exercise price	$ 1.67
Vested [Member] | Ranges Fourty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.7
Number outstanding (in Shares) | shares	218,500
Weighted average remaining contractual life (years)	5 months 19 days
Weighted Average Exercise price	$ 1.7
Vested [Member] | Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.75
Number outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	1 year 7 days
Weighted Average Exercise price	$ 1.75
Vested [Member] | Ranges Fourty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.78
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 2 months 4 days
Weighted Average Exercise price	$ 1.78
Vested [Member] | Ranges Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 2.31
Number outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	1 year 6 months 3 days
Weighted Average Exercise price	$ 2.31
Vested [Member] | Ranges Fourty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 4.15
Number outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 3 days
Weighted Average Exercise price	$ 4.15

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Employee [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.14	$ 0.67
Dividend yields
Weighted-average grant date fair value (in Dollars per share)	$ 0.13	$ 0.55
Employee [Member] | Minimum [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model [Line Items]
Expected volatility	127%	120%
Risk-free interest rates	1.37%	0.16%
Expected lives (in years)	5 years	3 years
Employee [Member] | Maximum [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model [Line Items]
Expected volatility	135%	143%
Risk-free interest rates	2.79%	0.84%
Expected lives (in years)	5 years 6 months	5 years
Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.14	$ 0.59
Dividend yields
Expected volatility		113%
Risk-free interest rates		1.07%
Expected lives (in years)	10 years	6 years
Weighted-average grant date fair value (in Dollars per share)	$ 0.13	$ 0.5
Non-Employees [Member] | Minimum [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model [Line Items]
Expected volatility	103%
Risk-free interest rates	1.78%
Non-Employees [Member] | Maximum [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted to employees and directors during the year, using the black scholes option-pricing model [Line Items]
Expected volatility	104%
Risk-free interest rates	2.83%

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of compensation cost of warrant and option issuances - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employees And Directors [Member]
Stockholders' Equity (Details) - Schedule of compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances	$ 417	$ 1,669	$ 631	$ 2,490
Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances	3		4	99
Unproved Oil & Gas properties [Member]
Stockholders' Equity (Details) - Schedule of compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances	$ 10		$ 17

Stockholders' Equity (Details_5

Stockholders' Equity (Details) - Schedule of warrants transactions	6 Months Ended
	Jun. 30, 2022 $ / shares shares
ZNWAA [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 2
Warrant Termination Date	Jan. 31, 2023
Outstanding Beginning Balance	1,498,804
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	1,498,804
Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Outstanding Beginning Balance	13,273,365
Warrants Issued	23,428,448
Warrants Exercised	(1,466,776)
Warrants Expired
Outstanding Ending Balance	35,234,937
Warrant Transactions [Member] | ZNWAD Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	May 02, 2023
Outstanding Beginning Balance	243,853
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	243,853
Warrant Transactions [Member] | ZNWAE Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	May 01, 2023
Outstanding Beginning Balance	2,144,099
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	2,144,099
Warrant Transactions [Member] | ZNWAF Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Aug. 14, 2023
Outstanding Beginning Balance	359,435
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	359,435
Warrant Transactions [Member] | ZNWAG Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Jan. 08, 2023
Outstanding Beginning Balance	240,068
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	240,068
Warrant Transactions [Member] | ZNWAH Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 5
Warrant Termination Date	Apr. 19, 2023
Outstanding Beginning Balance	372,400
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	372,400
Warrant Transactions [Member] | ZNWAI Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 3
Warrant Termination Date	Jun. 29, 2023
Outstanding Beginning Balance	640,710
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	640,710
Warrant Transactions [Member] | ZNWAJ [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Oct. 29, 2023
Outstanding Beginning Balance	545,900
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	545,900
Warrant Transactions [Member] | ZNWAK [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.01
Warrant Termination Date	Feb. 25, 2023
Outstanding Beginning Balance	431,675
Warrants Issued
Warrants Exercised	(6,650)
Outstanding Ending Balance	425,025
Warrant Transactions [Member] | ZNWAL [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 2
Warrant Termination Date	Aug. 26, 2023
Outstanding Beginning Balance	517,875
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	517,875
Warrant Transactions [Member] | ZNWAM Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	Jul. 15, 2023
Outstanding Beginning Balance	4,376,000
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	4,376,000
Warrant Transactions [Member] | ZNWAN Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 1
Warrant Termination Date	May 16, 2023
Outstanding Beginning Balance	267,660
Warrants Issued	100
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	267,760
Warrant Transactions [Member] | ZNWAO Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jun. 12, 2023
Outstanding Beginning Balance	174,970
Warrants Issued
Warrants Exercised	(310)
Warrants Expired
Outstanding Ending Balance	174,660
Warrant Transactions [Member] | ZNWAQ [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jul. 06, 2023
Outstanding Beginning Balance
Warrants Issued	23,428,348
Warrants Exercised
Warrants Expired
Outstanding Ending Balance	23,428,348
Warrant Transactions [Member] | ZNWAP Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jun. 02, 2023
Outstanding Beginning Balance	439,916
Warrants Issued
Warrants Exercised	(439,916)
Warrants Expired
Outstanding Ending Balance
Warrant Transactions [Member] | ZNWAR Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 0.25
Warrant Termination Date	Jun. 23, 2023
Outstanding Beginning Balance	1,020,000
Warrants Issued
Warrants Exercised	(1,020,000)
Warrants Expired
Outstanding Ending Balance

Stockholders' Equity (Details_6

Stockholders' Equity (Details) - Schedule of warrants to investors	6 Months Ended
	Jun. 30, 2022 $ / shares
ZNWAA Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	B,C	[1],[2]
Period of Grant	March 2013 – December 2014	[1],[2]
Exercise Price	$ 2	[1],[2]
Expiration Date	January 31, 2023	[1],[2]
ZNWAD Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	A,B,C	[1],[2],[3]
Period of Grant	January 2015 – March 2016	[1],[2],[3]
Exercise Price	$ 1	[1],[2],[3]
Expiration Date	May 02, 2023	[1],[2],[3]
ZNWAE Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	B,C	[1],[2]
Period of Grant	November 2016 – March 2017	[1],[2]
Exercise Price	$ 1	[1],[2]
Expiration Date	May 01, 2023	[1],[2]
ZNWAF Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	A,B,C	[1],[2],[3]
Period of Grant	May 2017 – July 2017	[1],[2],[3]
Exercise Price	$ 1	[1],[2],[3]
Expiration Date	August 14, 2023	[1],[2],[3]
ZNWAG Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	C	[2]
Period of Grant	October 2017 – December 2017	[2]
Exercise Price	$ 1	[2]
Expiration Date	January 08, 2023	[2]
ZNWAH Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	A,B,C	[1],[2],[3]
Period of Grant	February 2018	[1],[2],[3]
Exercise Price	$ 5	[1],[2],[3]
Expiration Date	April 19, 2023	[1],[2],[3]
ZNWAI Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	A,B,C	[1],[2],[3]
Period of Grant	April 2018 – May 2018	[1],[2],[3]
Exercise Price	$ 3	[1],[2],[3]
Expiration Date	June 29, 2023	[1],[2],[3]
ZNWAJ Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	B,C	[1],[2]
Period of Grant	August 2018 – September 2018	[1],[2]
Exercise Price	$ 1	[1],[2]
Expiration Date	October 29, 2023	[1],[2]
ZNWAK Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	B,C	[1],[2]
Period of Grant	December 2018 – January 2019	[1],[2]
Exercise Price	$ 0.01	[1],[2]
Expiration Date	February 25, 2023	[1],[2]
ZNWAL Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	C	[2]
Period of Grant	July 2019 – August 2019	[2]
Exercise Price	$ 2	[2]
Expiration Date	August 26, 2023	[2]
ZNWAM Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	D	[4]
Period of Grant	January 2021 – March 2021	[4]
Exercise Price	$ 1	[4]
Expiration Date	July 15, 2023	[4]
ZNWAN Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Period of Grant	May – June 2021
Exercise Price	$ 1
Expiration Date	May 16, 2023
ZNWAO Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Period of Grant	June 2021
Exercise Price	$ 0.25
Expiration Date	June 12, 2023
ZNWAQ Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	E	[5]
Period of Grant	June 2021	[5]
Exercise Price	$ 0.25	[5]
Expiration Date	July 6, 2023	[5]
ZNWAS Warrants [Member]
Stockholders' Equity (Details) - Schedule of warrants to investors [Line Items]
Name	F	[6]
Period of Grant	August 2021 – March 2022	[6]
Exercise Price	$ 0.25	[6]
Expiration Date	December 31, 2023	[6]
[1]On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.[2]On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.[3]On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year.[4]On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year.[5]These warrants were issued on May 5, 2022, and on May 17, 2022, the Company extended the expiration date of the Warrants by one (1) year.[6]These warrants will be exercisable beginning on November 15, 2023 and expire on December 31, 2023. These warrants will be issued in November 2023.

Unproved Oil and Gas Properti_3

Unproved Oil and Gas Properties, Full Cost Method (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Oil and Gas Property [Abstract]
Inclusive of non-cash amounts	$ 571,000	$ 460,000	$ 1,708,000	$ 2,902,000

Unproved Oil and Gas Properti_4

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of unproved oil and gas properties - Unproved Oil and Gas Properties, Full Cost Method [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Excluded from amortization base:
Drilling costs, and other operational related costs	$ 37,438	$ 32,075
Capitalized salary costs	2,279	2,158
Capitalized interest costs	1,418	1,418
Legal and seismic costs, license fees and other preparation costs	12,076	11,260
Other costs	39	39
Total unproved oil and gas properties	$ 53,250	$ 46,950

Unproved Oil and Gas Properti_5

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of changes in Unproved oil and gas properties - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022		Jun. 30, 2021		Jun. 30, 2022		Jun. 30, 2021
Excluded from amortization base:
Drilling costs, and other operational related costs	$ 4,735		$ 7,590		$ 5,363		$ 14,592
Capitalized salary costs	69		56		121		117
Capitalized interest costs			25				104
Legal costs, license fees and other preparation costs	347		728		816		1,762
Other costs
Total unproved oil and gas properties	$ 5,151	[1]	$ 8,399	[1]	$ 6,300	[2]	$ 16,575	[2]
[1] Inclusive of non-cash amounts of approximately $571,000, and $460,000 during the three months ended June 30, 2022, and 2021, respectively Inclusive of non-cash amounts of approximately $1,708,000, and $2,902,000 during the six months ended June 30, 2022, and 2021, respectively

Right of Use Lease Assets and_3

Right of Use Lease Assets and Lease Obligations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Right of Use Leases Assets and Leases Obligations [Abstract]
Operating lease costs	$ 68,000	$ 65,000	$ 137,000	$ 128,000
Operating lease liabilities	71,000	71,000	143,000	143,000
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 136,000	$ 128,000	$ 136,000	$ 128,000

Right of Use Lease Assets and_4

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of operating lease assets and liabilities - Rights use of assets [Member] - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Right of Use Lease Assets and Lease Obligations (Details) - Schedule of operating lease assets and liabilities [Line Items]
Operating lease assets	$ 335	$ 327
Current operating lease liabilities	261	203
Non-current operating lease liabilities	83	169
Total operating lease liabilities	$ 344	$ 372

Right of Use Lease Assets and_5

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	Jun. 30, 2022
Schedule of weighted average remaining lease term and weighted average discount rate for operating leases [Abstract]
Weighted average remaining lease term (years)	1 year 3 months 29 days
Weighted average discount rate	3.70%

Right of Use Lease Assets and_6

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of future minimum lease payments under non-cancellable operating leases $ in Thousands	Jun. 30, 2022 USD ($)
Schedule of future minimum lease payments under non-cancellable operating leases [Abstract]
2022	$ 140
2023	201
2024	12
2025
2026
Thereafter
Total undiscounted future minimum lease payments	353
Less: portion representing imputed interest	(9)
Total undiscounted future minimum lease payments	$ 344

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Commitments and Contingencies (Details) [Line Items]
Accrued license costs
Bank guarantees to government	$ 1,218,000	1,218,000
Bank guarantees to others	63,000	63,000
Aggregate guarantee amount	1,281,000	$ 1,281,000
Foreign currency exchange rate risks, description		A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels (“NIS”). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar (“USD”), our primary reporting currency. During the period January 1, 2022 through June 30, 2022, the USD has fluctuated by approximately 12.5% against the NIS (the USD strengthened relative to the NIS). By contrast, during the period January 1, 2021 through December 31, 2021, the USD fluctuated by approximately 3.3% against the NIS (the USD weakened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.
Cash equivalents and short-term bank deposits	$ 7,074,000	$ 7,074,000
US banks [Member]
Commitments and Contingencies (Details) [Line Items]
Interest rate	0.17%	0.34%

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Aug. 08, 2022
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Subsequent events description	(i)Approximately $533,000 was collected through the Company’s DSPP program during the period July 1 through August 8, 2022. (ii)Options to purchase 25,000 shares of Common Stock to one board member at an exercise price of $0.235 per share. The options vested upon grant and are exercisable through August 1, 2032. The fair value of the options at the date of grant amounted to approximately $5,875.